Monte Rosa Therapeutics down after increased $300 mln equity raise

Monte Rosa Therapeutics

09/01/2026 13:57

** Monte Rosa Therapeutics GLUE.O shares down 1.9% before the bell to $24.82 after $300 mln follow-on offering priced

    ** Boston, Massachusetts-based biotech late Thurs said it sold 12.5 mln shares, including ~1.4 mln pre-funded warrants, at $24, a 5.2% discount to last sale

      ** GLUE shares on Thurs finished session up ~9% at $25.31 after co launched $200 mln offering

    ** Stock on Weds surged 45% after co said its heart drug, MRT-8102, sharply lowered inflammation in an early-stage trial

    ** Co intends to use net proceeds to fund advancement of MRT-8102 in chronic inflammatory diseases including atherosclerotic cardiovascular disease (ASCVD), and for continued development of its QuEENTM platform, per the offering prospectus

    ** Jefferies, TD Cowen and Piper Sandler joint bookrunners; Wedbush and LifeSci Capital passive bookrunners

** Through Thurs, shares up 61% so far this year after 126% gain in 2025

    ** All 9 analysts are bullish on the stock; median PT $30, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))